Decision to acquire 12.15% stake in GPCR for new business, 10 billion won third-party allotment capital increase
The company decided to acquire a 12.15% stake in GPCR a biotech drug developer for approximately 10 billion won to secure new growth engines through new business initiatives.
The acquisition will be executed via three tranches of third-party allotment capital increases with payment dates on July 20 2026 September 21 2026 and November 20 2026 and the final acquisition date is November 21 2026.
Upon completion the company will become the largest shareholder of GPCR and the acquisition amount represents 10.51% of the company's equity.
GPCR reported sales of 2.5 billion won and net loss of 1.5 billion won in 2025 with impaired capital indicating weak financial health and there are plans for additional capital increases within six months posing investment risks.
This investment is focused on mid- to long-term synergies rather than short-term profit generation.
[AI Summary]The 10 billion won equity acquisition accounts for 10.51% of equity posing a significant financial burden and the target company's losses suggest potential impairment. Short-term stock price impact is likely limited but the company's strategic pivot to new business should be considered.
KOSDAQ Filing Information
Decision on Acquisition of Stocks and Investment Securities of Other Corporations